Sanara Medtech Inc (SMTI)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $300.83M
Last updated: Nov 17, 2026 at 4:15 PM ET
Sanara Medtech Inc (SMTI) Statistics
Sanara Medtech (SMTI) has a market cap of $300.83M and an enterprise value of $330.76M. Its return on invested capital of 16.87% compares with a 6.74% median across 7 similar companies.
Total Valuation
Enterprise value is 9.95% above the market cap, as debt exceeds cash.
| Market Cap | $300.83M |
|---|---|
| Enterprise Value | $330.76M |
| Latest price (Nov 17, 2026) | $32.73 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 11, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.6x and 37.5x. Its year-end P/S ranged from 1.8x to 18.6x from 2019 to 2025.
| Forward P/E | 156.5x |
|---|---|
| P/S Ratio | 2.6x |
| Forward P/S | 2.6x |
| P/B Ratio | 37.5x |
| P/OCF Ratio | 40.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 22.0x EBITDA.
| EV / Sales | 3.0x |
|---|---|
| EV / EBITDA | 22.0x |
| EV / EBIT | 28.5x |
Price Statistics
The stock is up 51.95% over 52 weeks and trades 3.42% below its 50-day average.
| Beta (1Y) | 0.49 |
|---|---|
| 52-Week Change | +51.95% |
| 1-Month Change | -1.24% |
| 3-Month Change | -4.52% |
| 6-Month Change | +44.06% |
| 5-Year Change | -5.93% |
| 10-Year Change | +557.92% |
| Total Return (1Y) | +51.95% |
| Total Return (3Y CAGR) | -0.36% |
| Total Return (5Y CAGR) | +1.07% |
| Return vs SPY (1Y) | +45.04% |
| Max Drawdown (1Y) | -36.94% |
| Max Drawdown (3Y) | -60.72% |
| Sharpe Ratio (1Y) | 0.91 |
| Correlation with SPY (1Y) | 0.14 |
| 50-Day Average | $33.89 |
| 200-Day Average | $26.09 |
| 52-Week Range | $16.05 to $35.52 |
| RSI (14 Days) | 48.5 |
| Average Volume (20 Days) | 64.55K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.24x current liabilities, and total debt is 6.10x shareholder equity.
| Current Ratio | 2.24x |
|---|---|
| Quick Ratio | 2.03x |
| Debt / Equity | 6.10x |
| Debt / EBITDA | 3.24x |
| Interest Coverage | 1.60x |
Returns and Efficiency
Return on invested capital is 16.87% over the last 12 months, against a 5-year average of -4.79%.
| Return on Equity (ROE) | -39.34% |
|---|---|
| Return on Assets (ROA) | -4.17% |
| Return on Invested Capital (ROIC) | 16.87% |
| Return on Capital Employed (ROCE) | 20.76% |
| ROA (5Y Average) | -20.80% |
| ROIC (5Y Average) | -4.79% |
| Asset Turnover | 1.56x |
| Inventory Turnover | 2.33x |
| Receivables Turnover | 7.93x |
| Cash Conversion Cycle | 50 days |
Scores
SMTI has an Altman Z-Score of 3.61, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.61 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $111.88M over the last 12 months is up 9.82% from the 12 months before.
| Revenue | $111.88M |
|---|---|
| Revenue Growth (YoY) | +9.82% |
| Gross Profit | $104.00M |
| Operating Income | $11.64M |
| Pretax Income | $3.03M |
| Net Income | -$3.02M |
| EBITDA | $14.40M |
| EBIT | $11.62M |
| Reported EPS (TTM) | $0.02 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 10.62% of the $72.24M in total assets.
| Cash and Equivalents | $16.79M |
|---|---|
| Total Debt | $46.72M |
| Net Debt | $29.94M |
| Net Debt Per Share | $3.41 |
| Working Capital | $20.12M |
| Shareholder Equity | $7.67M |
| Book Value Per Share | $0.87 |
| Tangible Book Value | -$12.63M |
| Total Assets | $72.24M |
| Total Liabilities | $64.57M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $7.42M |
|---|---|
| FCF Per Share | $0.79 |
| Depreciation and Amortization | $2.78M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 10.40%, against a 5-year average of -11.16%.
| Gross Margin | 92.95% |
|---|---|
| Operating Margin | 10.40% |
| Pretax Margin | 2.71% |
| Net Margin | -2.70% |
| EBITDA Margin | 12.87% |
| EBIT Margin | 10.38% |
| Gross Margin (5Y Average) | 89.56% |
| Operating Margin (5Y Average) | -11.16% |
| Net Margin (5Y Average) | -21.09% |
Growth
Revenue grew 31.03% a year over 3 years.
| Revenue Growth (3Y CAGR) | +31.03% |
|---|---|
| Revenue Growth (5Y CAGR) | +45.92% |
| Book Value Per Share Growth (2Y CAGR) | -63.79% |
Stock Splits
The last split was a 1-for-100 reverse split on May 10, 2019.
| Last Split Date | May 10, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:100 |
Peer Position
Against 12 similar companies, SMTI has the 9th highest P/S.
P/S RatioPeer median 3.0x
ROICPeer median 6.74%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.20%
| P/S Ratio | 2.6x vs 3.0x median |
|---|---|
| ROIC | 16.87% vs 6.74% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.82% vs +8.20% median |
Analyst Forecast
Consensus estimates put revenue growth at 13.65% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +13.65% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SMTI
What is SMTI's market cap?
Sanara Medtech has a market cap of $300.83M. Its enterprise value, which adds debt and subtracts cash, is $330.76M.
How many shares of SMTI are outstanding?
Sanara Medtech has 8.78M shares outstanding. The count is up 1.58% from a year earlier.
Does SMTI pay a dividend?
No. Sanara Medtech does not pay a dividend.
How much debt does SMTI have?
Sanara Medtech has $46.72M of total debt and $16.79M of cash and equivalents, a net debt position of $29.94M.
SMTI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors